1887

Abstract

The occurrence and development of diabetic nephropathy (DN) are closely related to gut microbiota. is a medicinal and edible fungus. is a therapeutic material for unifying Chinese Qi. They can delay the occurrence and development of kidney disease. In recent years, solid-state fermentation of edible fungi and traditional Chinese medicine has become a hot issue.

We assumed that solid-state fermentation products of and (RPF) could ameliorate diabetic nephropathy and modulate gut microbiota composition.

We aimed to study the function and mechanism of the RPF for ameliorating DN in mice.

We investigated the effect of the potential roles of RPF in DN mice and interaction between DN and gut microbiota using animal experiments and gut microbiota measurements.

We found that RPF dramatically reduced urine protein, serum creatinine and blood urea nitrogen in DN mice. Furthermore, RPF ameliorated the physiological condition of DN mice by regulating the abundance of intestinal microbiota such as , , and .

RPF can ameliorate diabetic nephropathy and modulate gut microbiota composition.

Funding
This study was supported by the:
  • National Natural Science Foundation of China (Award 82174093)
    • Principle Award Recipient: XinyuanShi
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001535
2022-05-26
2022-07-06
Loading full text...

Full text loading...

References

  1. Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. Sci World J 2009; 9:1127–1139 [View Article] [PubMed]
    [Google Scholar]
  2. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352:213–219 [View Article] [PubMed]
    [Google Scholar]
  3. Xue R, Gui D, Zheng L, Zhai R, Wang F et al. Mechanistic insight and management of diabetic nephropathy: recent progress and future perspective. J Diabetes Res 2017; 2017:1839809 [View Article] [PubMed]
    [Google Scholar]
  4. Raval N, Kumawat A, Kalyane D, Kalia K, Tekade RK. Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities. Drug Discov Today 2020; 25:862–878 [View Article] [PubMed]
    [Google Scholar]
  5. Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15:1546–1558 [View Article] [PubMed]
    [Google Scholar]
  6. Yang T, Richards EM, Pepine CJ, Raizada MK. The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease. Nat Rev Nephrol 2018; 14:442–456 [View Article] [PubMed]
    [Google Scholar]
  7. Vaziri ND. Effect of synbiotic therapy on gut-derived uremic toxins and the intestinal microbiome in patients with CKD. Clin J Am Soc Nephrol 2016; 11:199–201 [View Article] [PubMed]
    [Google Scholar]
  8. Mishima E, Fukuda S, Mukawa C, Yuri A, Kanemitsu Y et al. Evaluation of the impact of gut microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics approach. Kidney Int 2017; 92:634–645 [View Article] [PubMed]
    [Google Scholar]
  9. Chaves LD, McSkimming DI, Bryniarski MA, Honan AM, Abyad S et al. Chronic kidney disease, uremic milieu, and its effects on gut bacterial microbiota dysbiosis. Am J Physiol Renal Physiol 2018; 315:F487–F502 [View Article] [PubMed]
    [Google Scholar]
  10. Rocco MV. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60:850–886 [View Article] [PubMed]
    [Google Scholar]
  11. Kim H-J, Lee M-H, Jo S-H, Seo W-W, Kim SE et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease- propensity score matching analysis. Circ J 2019; 84:83–90 [View Article] [PubMed]
    [Google Scholar]
  12. Fu J, Wang Z, Huang L, Zheng S, Wang D et al. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi). Phytother Res 2014; 28:1275–1283 [View Article] [PubMed]
    [Google Scholar]
  13. Ai P, Yong G, Dingkun G, Qiuyu Z, Kaiyuan Z et al. Aqueous extract of Astragali Radix induces human natriuresis through enhancement of renal response to atrial natriuretic peptide. J Ethnopharmacol 2008; 116:413–421 [View Article] [PubMed]
    [Google Scholar]
  14. Zhang L, Shergis JL, Yang L, Zhang AL, Guo X et al. Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis. J Ethnopharmacol 2019; 239:111921 [View Article] [PubMed]
    [Google Scholar]
  15. Wang Y, He P, He L, Huang Q, Cheng J et al. Structural elucidation, antioxidant and immunomodulatory activities of a novel heteropolysaccharide from cultured Paecilomyces cicadae (Miquel.) Samson. Carbohydr Polym 2019; 216:270–281 [View Article] [PubMed]
    [Google Scholar]
  16. Cao T, Xu R, Xu Y, Liu Y, Qi D et al. The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro. Int Urol Nephrol 2019; 51:1883–1892 [View Article] [PubMed]
    [Google Scholar]
  17. Jun KB, Lin LC. Cordyceps cicadae NTTU 868 mycelium prevents ccl 4 -induced hepatic fibrosis in BALB/c mice via inhibiting the expression of pro-inflammatory and pro-fibrotic cytokines. J Funct Foods 2017; 43:214–223
    [Google Scholar]
  18. Li L, Wang L, Fan W, Jiang Y, Zhang C et al. The Application of Fermentation Technology in Traditional Chinese Medicine: A Review. Am J Chin Med 2020; 48:899–921 [View Article] [PubMed]
    [Google Scholar]
  19. Zhao CY, Yang F, QU QS, LIU ZY, Gao PF et al. Establishment of bidirectional fermentation system of paecilomyces cicadae /astragalus membranaceus and study on its components. WCM 2018; 13:3195–3198
    [Google Scholar]
  20. Guo H, Wang Y, Zhang X, Zang Y, Zhang Y et al. Astragaloside IV protects against podocyte injury via SERCA2-dependent ER stress reduction and AMPKα-regulated autophagy induction in streptozotocin-induced diabetic nephropathy. Sci Rep 2017; 7:6852 [View Article] [PubMed]
    [Google Scholar]
  21. Wang Q, Zhao LH, Di S. Exploration about the clinical application and dosage of astragalus. Jilin J Chin Med 2018; 38:1450–1454
    [Google Scholar]
  22. Aziz KMA. Correlation of urine biomarkers: microalbuminuria and spot urine protein among diabetic patients. application of spot urine protein in diabetic kidney disease, nephropathy, proteinuria estimation, diagnosing and monitoring. Recent Pat Endocr Metab Immune Drug Discov 2015; 9:121–133 [View Article] [PubMed]
    [Google Scholar]
  23. Li M, Wang W, Xue J, Gu Y, Lin S. Meta-analysis of the clinical value of Astragalus membranaceus in diabetic nephropathy. J Ethnopharmacol 2011; 133:412–419 [View Article] [PubMed]
    [Google Scholar]
  24. Goh S-Y, Jasik M, Cooper ME. Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs 2008; 13:447–463 [View Article] [PubMed]
    [Google Scholar]
  25. Li X-W, Chen H-P, He Y-Y, Chen W-L, Chen J-W et al. Effects of rich-polyphenols extract of Dendrobium loddigesii on anti-diabetic, anti-inflammatory, anti-oxidant, and gut microbiota modulation in db/db Mice. Molecules 2018; 23:3245 [View Article]
    [Google Scholar]
  26. Xu K-Y, Xia G-H, Lu J-Q, Chen M-X, Zhen X et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep 2017; 7:1445 [View Article] [PubMed]
    [Google Scholar]
  27. Chen R, Wang J, Zhan R, Zhang L, Wang X. Fecal metabonomics combined with 16S rRNA gene sequencing to analyze the changes of gut microbiota in rats with kidney-yang deficiency syndrome and the intervention effect of You-gui pill. J Ethnopharmacol 2019; 244:112139 [View Article] [PubMed]
    [Google Scholar]
  28. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A et al. A core gut microbiome in obese and lean twins. Nature 2009; 457:480–484 [View Article] [PubMed]
    [Google Scholar]
  29. Wu R, Zhao D, An R, Wang Z, Li Y et al. Linggui zhugan formula improves glucose and lipid levels and alters gut microbiota in high-fat diet-induced diabetic mice. Front Physiol 2019; 10:918 [View Article] [PubMed]
    [Google Scholar]
  30. Brugman S, Klatter FA, Visser JTJ, Wildeboer-Veloo ACM, Harmsen HJM et al. Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-prone rat. Is the gut flora involved in the development of type 1 diabetes?. Diabetologia 2006; 49:2105–2108 [View Article] [PubMed]
    [Google Scholar]
  31. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS ONE 2010; 5:e9085 [View Article] [PubMed]
    [Google Scholar]
  32. Murugesan S, Nirmalkar K, Hoyo-Vadillo C, García-Espitia M, Ramírez-Sánchez D et al. Gut microbiome production of short-chain fatty acids and obesity in children. Eur J Clin Microbiol Infect Dis 2018; 37:621–625 [View Article] [PubMed]
    [Google Scholar]
  33. Meehan CJ, Beiko RG. A phylogenomic view of ecological specialization in the Lachnospiraceae, A family of digestive tract-associated bacteria. Genome Biol Evol 2014; 6:703–713 [View Article] [PubMed]
    [Google Scholar]
  34. Menni C, Lin C, Cecelja M, Mangino M, Matey-Hernandez ML et al. Gut microbial diversity is associated with lower arterial stiffness in women. Eur Heart J 2018; 39:2390–2397 [View Article] [PubMed]
    [Google Scholar]
  35. Tang WHW, Wang Z, Kennedy DJ, Wu Y, Buffa JA et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res 2015; 116:448–455 [View Article] [PubMed]
    [Google Scholar]
  36. Saleem T, Dahpy M, Ezzat G, Abdelrahman G, Abdel-Aziz E et al. The profile of plasma free amino acids in type 2 diabetes mellitus with insulin resistance: association with microalbuminuria and macroalbuminuria. Appl Biochem Biotechnol 2019; 188:854–867 [View Article]
    [Google Scholar]
  37. Cox LM, Yamanishi S, Sohn J, Alekseyenko AV, Leung JM et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell 2014; 158:705–721 [View Article] [PubMed]
    [Google Scholar]
  38. Kameyama K, Itoh K. Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. Microbes Environ 2014; 29:427–430 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001535
Loading
/content/journal/jmm/10.1099/jmm.0.001535
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error